New Migraine Prevention Guidelines Emphasize CGRP Drugs and Expanded Patient Eligibility
Source Summary
The American Academy of Neurology and American Headache Society have released updated guidance to help clinicians select the most effective migraine prevention medications for individual patients. The guidelines highlight CGRP drugs and indicate broad eligibility criteria for their use.
Why it matters
These guidelines provide clinicians with evidence-based recommendations to optimize migraine prevention treatment selection and potentially improve patient outcomes.
